Masimo Corporation (MASI) Hisse Analizi
Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
178.04$'dan işlem gören Masimo Corporation (MASI), 10B değerindeki bir Healthcare şirketidir. Hisse senedi, 9 kantitatif KPI'ya dayalı olarak orta dereceli bir derecelendirme olan 55/100 puan alıyor.
Son analiz: 8 Şub 2026Masimo Corporation (MASI) Sağlık ve Boru Hattı Genel Bakışı
Masimo Corporation pioneers noninvasive patient monitoring with its breakthrough Masimo SET pulse oximetry, offering superior accuracy and reliability compared to conventional methods, positioning them as a leader in hospital automation and patient safety solutions with a global reach.
Yatırım Tezi
Masimo presents a notable research candidate due to its leadership in noninvasive monitoring technologies and its expanding presence in hospital automation. The company's Masimo SET pulse oximetry is a gold standard in the industry, driving consistent revenue. Growth catalysts include the increasing adoption of its rainbow SET platform and hospital automation solutions, which offer higher margins and recurring revenue streams. The company's focus on innovation and patient safety positions it well to capitalize on the growing demand for advanced monitoring technologies. While the current P/E ratio is negative, the potential for improved profitability and expansion into new markets makes Masimo an attractive long-term investment. Monitor gross margins (currently 55.0%) for signs of improvement.
FMP finansallarına ve nicel analizine dayanmaktadır
Temel Önemli Noktalar
- Market Cap of $7.47B reflects Masimo's significant presence in the medical technology sector.
- Gross Margin of 55.0% indicates strong pricing power and efficient operations in its core business.
- Negative P/E Ratio of -13.20 suggests current challenges in profitability, requiring close monitoring.
- Masimo SET pulse oximetry is the gold standard in the industry, driving consistent revenue.
- Beta of 1.26 indicates higher volatility compared to the market, reflecting growth potential and associated risks.
Rakipler & Benzerleri
Güçlü Yönler
- Proprietary Masimo SET technology.
- Strong brand reputation.
- Extensive patent portfolio.
- Integrated hospital automation platform.
Zayıflıklar
- High reliance on pulse oximetry sales.
- Negative profit margin.
- Exposure to regulatory and pricing pressures.
- Dependence on third-party distributors and OEM partners.
Katalizörler
- Ongoing: Increasing adoption of rainbow SET platform.
- Ongoing: Expansion of hospital automation solutions.
- Upcoming: New product launches in neuromodulation.
- Ongoing: Geographic expansion into emerging markets.
Riskler
- Potential: Competition from established medical device companies.
- Potential: Technological obsolescence.
- Ongoing: Regulatory and pricing pressures.
- Potential: Product liability claims.
- Ongoing: Negative profit margin.
Büyüme Fırsatları
- Expansion of Rainbow SET Platform: The Masimo rainbow SET platform, which noninvasively monitors multiple blood constituents, presents a significant growth opportunity. As healthcare providers increasingly seek comprehensive patient monitoring solutions, the demand for rainbow SET is expected to rise. The market for multi-parameter monitoring is estimated to reach billions of dollars, offering Masimo a substantial revenue opportunity. Timeline: Ongoing.
- Growth in Hospital Automation: Masimo's Hospital Automation platform, including Patient SafetyNet and UniView, offers significant growth potential. By integrating patient data and streamlining clinical workflows, these solutions improve patient safety and reduce healthcare costs. The market for hospital automation is projected to grow, driven by the increasing adoption of electronic health records and the need for greater efficiency in healthcare delivery. Timeline: Ongoing.
- Penetration of Consumer Market: Masimo's e-commerce site, masimopersonalhealth.com, provides a direct channel to consumers, offering an opportunity to expand beyond the traditional hospital setting. By offering personal health monitoring devices, Masimo can tap into the growing market for remote patient monitoring and wellness solutions. This market is driven by increasing consumer awareness of health and wellness and the desire for convenient and accessible monitoring tools. Timeline: Ongoing.
- Geographic Expansion: Masimo has the opportunity to expand its presence in emerging markets, where healthcare infrastructure is developing and the demand for advanced monitoring technologies is growing. By leveraging its existing distribution network and establishing partnerships with local healthcare providers, Masimo can capitalize on the growth potential in these markets. Timeline: Ongoing.
- Innovation in Neuromodulation: Masimo's entry into neuromodulation solutions represents a new growth avenue. As the demand for non-pharmacological pain management and therapeutic interventions grows, Masimo's neuromodulation technologies can address a significant market need. Further investment in research and development in this area can position Masimo as a leader in innovative neuromodulation solutions. Timeline: Ongoing.
Fırsatlar
- Expansion of rainbow SET platform.
- Growth in hospital automation.
- Penetration of consumer market.
- Geographic expansion into emerging markets.
Tehditler
- Competition from established medical device companies.
- Technological obsolescence.
- Product liability claims.
- Economic downturns affecting hospital budgets.
Rekabet Avantajları
- Proprietary Masimo SET technology provides superior accuracy and reliability in pulse oximetry.
- Strong brand reputation and established relationships with key healthcare providers.
- Extensive patent portfolio protects its intellectual property.
- Integrated hospital automation platform creates switching costs for customers.
MASI Hakkında
Masimo Corporation, founded in 1989 and headquartered in Irvine, California, is a global medical technology innovator. The company specializes in developing, manufacturing, and marketing a suite of noninvasive monitoring technologies and hospital automation solutions. Masimo's core innovation is its Signal Extraction Technology (SET) pulse oximetry, designed to overcome the limitations of traditional pulse oximetry, particularly in situations involving patient motion and low perfusion. This technology provides clinicians with more accurate and reliable oxygen saturation measurements, enhancing patient safety. Beyond pulse oximetry, Masimo offers the rainbow SET platform, which noninvasively monitors various blood constituents, including hemoglobin levels, carboxyhemoglobin, and methemoglobin. The company's product portfolio also includes SedLine brain function monitoring, capnography and gas monitoring, O3 regional oximetry, and hemodynamic monitoring solutions. Masimo's Hospital Automation platform, featuring products like Patient SafetyNet and UniView, integrates patient data and streamlines clinical workflows. Masimo distributes its products through a direct sales force, distributors, and original equipment manufacturer (OEM) partners, serving hospitals, emergency medical services, home care providers, long-term care facilities, physician offices, veterinarians, and consumers. The company also sells non-medical/consumer products through its e-commerce site, masimopersonalhealth.com. Masimo's commitment to innovation and patient safety has established it as a key player in the medical technology industry.
Ne Yaparlar
- Develops and manufactures noninvasive patient monitoring technologies.
- Offers Masimo SET pulse oximetry for accurate oxygen saturation measurement.
- Provides rainbow SET platform for monitoring multiple blood constituents.
- Offers SedLine brain function monitoring technology.
- Provides capnography and gas monitoring products.
- Offers O3 regional oximetry for tissue oxygen saturation measurement.
- Provides hemodynamic monitoring solutions.
- Offers hospital automation solutions through Patient SafetyNet and UniView.
İş Modeli
- Sells noninvasive monitoring devices and sensors to hospitals and healthcare providers.
- Generates recurring revenue through the sale of disposable sensors and consumables.
- Offers hospital automation solutions on a subscription basis.
- Partners with original equipment manufacturers (OEMs) to integrate its technologies into their products.
Sektör Bağlamı
Masimo operates in the medical instruments and supplies industry, a sector characterized by continuous innovation and increasing demand for advanced monitoring technologies. The global market for patient monitoring devices is expected to grow, driven by the aging population, rising prevalence of chronic diseases, and increasing adoption of remote patient monitoring solutions. Masimo competes with companies like ABVX, ATR, AVTR, BAX and BIO, focusing on differentiating itself through its proprietary Masimo SET technology and integrated hospital automation platforms. The industry is also subject to regulatory scrutiny and pricing pressures, requiring companies to demonstrate clinical and economic value.
Kilit Müşteriler
- Hospitals and acute care facilities.
- Emergency medical service providers.
- Home care providers.
- Long-term care facilities.
- Physician offices and clinics.
- Veterinarians.
Finansallar
Grafik & Bilgi
Masimo Corporation (MASI) hisse senedi fiyatı: $178.04 (-0.66, -0.37%)
Son Haberler
-
This $7 Million Masimo Exit Came Before a 34% Surge on $9.9 Billion Acquisition
fool.com · 22 Mar 2026
-
Market Chatter: Judge Rules Apple's Redesigned Watch Doesn't Infringe Patents
MT Newswires · 19 Mar 2026
-
Are ACLX, MASI, FONR Obtaining Fair Deals for their Shareholders?
prnewswire.com · 19 Mar 2026
-
3 Overrated Stocks We Steer Clear Of
Yahoo! Finance: MASI News · 16 Mar 2026
Analist Konsensüsü
Fikir Birliği Derecelendirmesi
MASI için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.
Fiyat Hedefleri
Konsensüs hedefi: $180.00
MoonshotScore
Bu puan ne anlama geliyor?
MoonshotScore, MASI'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.
Rakipler & Benzerleri
Son Haberler
This $7 Million Masimo Exit Came Before a 34% Surge on $9.9 Billion Acquisition
Market Chatter: Judge Rules Apple's Redesigned Watch Doesn't Infringe Patents
Are ACLX, MASI, FONR Obtaining Fair Deals for their Shareholders?
3 Overrated Stocks We Steer Clear Of
MASI Healthcare Hisse Senedi SSS
MASI için değerlendirilmesi gereken temel faktörler nelerdir?
Masimo Corporation (MASI) şu anda yapay zeka skoru 55/100, orta puanı gösteriyor. Analist hedefi $180.00 ($178.04'dan +1%). Temel güçlü yan: Proprietary Masimo SET technology.. İzlenmesi gereken birincil risk: Potential: Competition from established medical device companies.. Bu bir finansal tavsiye değildir.
MASI MoonshotScore'u nedir?
MASI şu anda MoonshotScore'da 55/100 (Derece C) alıyor, bu da orta derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.
MASI verileri ne sıklıkla güncellenir?
MASI fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.
Analistler MASI hakkında ne diyor?
Analistler, MASI için $180.00 konsensüs fiyat hedefi belirledi, bu mevcut fiyattan ($178.04) yukarı yönlü %1 potansiyeli temsil ediyor. Kapsam, al, tut ve sat derecelendirmelerini, kazanç tahminlerini ve son yükseltmeleri veya düşürmeleri içerir. Tüm ayrıntılar için bu sayfadaki Analist Konsensüsü bölümüne bakın.
MASI'a yatırım yapmanın riskleri nelerdir?
MASI için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Competition from established medical device companies.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.
MASI'ın P/E oranı nedir?
MASI için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için MASI'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.
MASI aşırı değerli mi, yoksa düşük değerli mi?
Masimo Corporation (MASI)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Analist hedefi $180.00 (mevcut fiyattan +1%), analistlerin hisse senedini adil değere yakın gördüğünü gösteriyor. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.
MASI'ın temettü verimi nedir?
Masimo Corporation (MASI) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.
Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.
Resmi Kaynaklar
Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.
- Financial data is based on the most recently available information.
- Forward-looking statements are subject to risks and uncertainties.